Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
2
×
crispr
2
×
detroit blog main
detroit top stories
eli lilly
gene therapy
2
×
gilead sciences
glaxosmithkline
indiana blog main
indiana top stories
johnson & johnson
life sciences
multiple myeloma
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
adalimumab (humira)
aducanumab
aduro biotech
affordable care act
alector
What
bio
2
×
new
2
×
roundup
approval
biogen’s
biopharma
biopharmaceutical
companies
congress
congressional
convo
crispr
drug
earlier
executives
failures
feud
group
isn’t
known
later
littered
month
nash
news
ny
pharma
price
remains
road
roster
spectacles
splash
stay
strategy
talk
testify
tuned
vs
you’re
Language
Current search:
bio
×
new
×
crispr
×
" gene therapy "
×
" clinical trials "
×
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More